Efficacy of canagliflozin vs metformin in women with polycystic ovary syndrome: A randomized, open label, non‐inferiority trial
Diabetes, Obesity and Metabolism Nov 05, 2021
Cai M, Shao X, Xing F, et al. - A single center, prospective, randomized open-label (ratio 1:1) non-inferiority trial comparing the safety and efficacy of canagliflozin vs metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR).
Researchers administered either 100 mg (n = 33) canagliflozin daily or 1,500–2,000 mg metformin daily (n = 35) for 12 weeks to women aged 18–45 years with PCOS and IR.
Outcomes suggest non-inferiority of canagliflozin to metformin in lowering of HOMA-IR after 12 weeks of treatment.
Significant improvement in menstrual pattern, reduction in body weight and total fat mass, and lowering of triglyceride levels could be achieved by administering with both canagliflozin and metformin.
There were significant advantages in reducing uric acid and dehydroepiandrosterone sulfate levels in correlation with providing canagliflozin vs metformin.
The main adverse events in the metformin group and canagliflozin group were pruritus vulvae (9.09%) and gastrointestinal reaction (55.55%), respectively.
In view of the noninferiority of canagliflozin to metformin in PCOS patients with IR, researchers herein support considering sodium-glucose co-transporter 2 inhibitors as effective drugs in the treatment of PCOS patients with IR.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries